Kornitzer Capital Management Inc. KS Takes Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Kornitzer Capital Management Inc. KS acquired a new position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 33,000 shares of the biotechnology company's stock, valued at approximately $566,000.

Other large investors have also modified their holdings of the company. D.A. Davidson & CO. bought a new position in ADMA Biologics during the fourth quarter worth $202,000. Principal Financial Group Inc. grew its position in ADMA Biologics by 5.4% in the 4th quarter. Principal Financial Group Inc. now owns 1,259,014 shares of the biotechnology company's stock worth $21,592,000 after purchasing an additional 64,793 shares during the last quarter. Nkcfo LLC bought a new position in shares of ADMA Biologics during the 4th quarter worth about $325,000. Rhumbline Advisers raised its position in shares of ADMA Biologics by 1.0% during the fourth quarter. Rhumbline Advisers now owns 621,079 shares of the biotechnology company's stock valued at $10,651,000 after buying an additional 5,881 shares during the last quarter. Finally, New York State Teachers Retirement System grew its position in ADMA Biologics by 24.1% during the fourth quarter. New York State Teachers Retirement System now owns 113,090 shares of the biotechnology company's stock worth $1,939,000 after buying an additional 21,976 shares in the last quarter. 75.68% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on ADMA shares. Raymond James raised their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Friday, November 8th. HC Wainwright boosted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, November 8th.

ADMA Biologics Stock Down 1.8 %

Shares of NASDAQ ADMA traded down $0.28 during midday trading on Friday, reaching $15.80. The company's stock had a trading volume of 1,021,562 shares, compared to its average volume of 2,257,449. ADMA Biologics, Inc. has a fifty-two week low of $5.08 and a fifty-two week high of $23.64. The stock has a market capitalization of $3.73 billion, a price-to-earnings ratio of 56.45 and a beta of 0.75. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock has a 50 day simple moving average of $17.03 and a 200-day simple moving average of $17.88.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.